Mycoplasma pneumoniae (39 strains) was most susceptible to two quinolones, WIN 57273 and sparfloxacin, with MICs for 90% of the strains (MIC90s) of 0.125 and 0.25 ,Lg/ml, respectively. It was susceptible to ofloxacin and ciprofloxacin at 2 ,ug/ml and to lomefloxacin and fleroxacin at 4 ,ug/ml. The MIC90 of erythromycin was 0.062 ,ug/ml, and that of tetracycline was 1 ,Lg/ml. Mycoplasma pneumoniae is a major cause of pneumonia and accounts for as much as 20% of total pneumonia (2). The recommended therapies are tetracycline or erythromycin, both of which are efficacious in reducing the duration of symptoms (21). Because of the increasing resistance of conventional bacteria to penicillin and tetracycline (18), the quinolones (26) may be used more frequently. Accordingly, it will be of increasing importance to know the comparative susceptibilities of clinical strains of M. pneumoniae to various quinolones. In this study, we report the susceptibilities of M. pneumoniae to quinolones, tetracycline, and erythromycin as determined by the agar dilution method.
Mycoplasma pneumoniae is a major cause of pneumonia and accounts for as much as 20% of total pneumonia (2) . The recommended therapies are tetracycline or erythromycin, both of which are efficacious in reducing the duration of symptoms (21) . Because of the increasing resistance of conventional bacteria to penicillin and tetracycline (18) , the quinolones (26) may be used more frequently. Accordingly, it will be of increasing importance to know the comparative susceptibilities of clinical strains of M. pneumoniae to various quinolones. In this study, we report the susceptibilities of M. pneumoniae to quinolones, tetracycline, and erythromycin as determined by the agar dilution method.
The reference strains of M. pneumoniae used were AP-164 (8) and the type strain FH (16) . Thirty-seven clinical isolates from Seattle were tested, which included the 12 strains from 1964 to 1974 which have been compared antigenically (24) . The clinical isolates were tested within five passages from the patient. Strains were stored frozen at -70°C. Inocula for susceptibility testing were grown in a broth medium consisting of dialysate broth (6) supplemented with 20% horse serum, 5 mM glucose, 0.001% phenol red, and penicillin at 200 U/ml. Broth cultures were used for inocula no more than 2 days after the pH began to drop as judged by a change in the pH indicator (usually 3 to 5 days when a culture was diluted 1:100 into fresh medium). The agar dilution susceptibility testing procedure closely followed that described for Mycoplasma hominis (9) . Briefly, portions (25 ml) of H agar (7) containing various quantities of antimicrobial agent were poured into plastic petri dishes (100 mm square), and plates were held for 48 h in the dark at room temperature to eliminate excess surface moisture. The soy peptone used for both H agar and dialysate broth was obtained from Sheffield Chemical (Norwich, N.Y.), and the media were prepared as described previously (6, 7) . Plates were inoculated with 25-pd samples of cultures diluted 1:10, 1:100, and 1:1,000 by using a Steers replicator (23) . Plates were incubated in the dark in a moist atmosphere of 5% CO2 in air and observed at 8, 16 , and 25 days with a dissecting microscope at x40 magnification. The pH of the agar was 6.85, and the agar remained at that pH throughout incubation. The MIC was the least amount of antimicrobial agent which completely prevented the formation of 30 to 300 colonies on a spot as determined by colony count of spots on control plates (9) . ). Quinolones (10 mg) were suspended in 10 ml of H20, and 0.025 ml of 10 N NaOH was added to aid solublilization. Erythromycin was dissolved in 10% ethanol in water, and tetracycline was dissolved in water. Fresh preparations were made up on the day of the test and sterilized by filtration through an 0.22-,um-pore-size filter (Millipore Corp., Bedford, Mass.).
The susceptibilities of 39 strains were determined by the agar dilution method, with the endpoint observed at day 16 (Table 1 ). M. pneumoniae was highly susceptible to WIN 57273 and sparfloxacin, with MIC90s of 0.125 and 0.25 ,ug/ml, respectively, values which approach the MIC90 of 0.062 ,ug/ml found for erythromycin (Table 1) . Nakamura et al.
found a value of 0.1 j,g/ml for sparfloxacin by the agar dilution method (12) . The MIC90s of 2 ,ug/ml for ciprofloxacin and ofloxacin and 4 ,ug/ml for fleroxacin and lomefloxacin are close to the levels attainable in tissue (26) . In other studies, the MIC90 of ciprofloxacin was 0.25 to 1.0 jg/ml by broth dilution (1) and 1 ,ug/ml by agar dilution (12, 17) . MIC90s of ofloxacin were 0.8 to 1.6 ,ug/ml (15) by broth dilution and 1 pug/ml by agar dilution (12, 17) . The range in susceptibility for each quinolone was narrow (Table 1) : thus, there was no evidence of resistance of any of these strains or a change in susceptibility over time.
The susceptibilities of M. pneumoniae to ofloxacin, fleroxacin, and lomefloxacin were about twofold less than those for Mycoplasma hominis and about the same as those for Ureaplasma urealyticum (9) . In the case of ciprofloxacin, M. pneumoniae was twofold less susceptible than M. hominis and fourfold more susceptible than U. urealyticum. The susceptibilities of M. pneumoniae to quinolones roughly parallel the susceptibilities of gram-positive bacteria to the same quinolones (5, 12, 26) , a result similar to our previous data for M. hominis and U. urealyticum (9) . The two most active compounds against M. pneumoniae, WIN 57273 and sparfloxacin, also had the highest activities against grampositive bacteria among the quinolones tested (5, 12) . (4, 14, 15, 22, 25) and 0.1 to 1.0 ,ig/ml (20) . By agar dilution, MICs of 0.008 to 0.063 ,ug/ml (3, 11, 19) and 0.8 to 1.6 ,ug/ml (10) have been reported. These differences are probably not the result of low-level resistance to erythromycin since the strains reported as resistant have been highly resistant (400 jig/ml [13] ).
Standardization of susceptibility testing of M. pneumoniae is difficult because of the slow growth of the organism even though the agar medium contains 20% serum. For quinolones, changes in the incubation period made only a twofold difference in MIC, whereas four-to eightfold differences were found with erythromycin and tetracycline. Incubation periods of 7 days could be used for determination of quinolone endpoints, but an incubation period of as much as 14 days appears necessary for determination of susceptibilities to tetracycline and erythromycin. Although these results do not predict how effective quinolones might be in treatment of M. pneumoniae pneumonia, they provide a ranking of the relative activities of a number of newer quinolones. 
